Yudong Sun1, Zhiqing Zhao1, Lewei Hou2, Yu Xiao1, Feng Qin1, Junyi Yan1, Jian Zhou3, Zaiping Jing4. 1. Department of Vascular Surgery, Changhai Hospital, Second Military Medical University, Shanghai, China. 2. Department of General Surgery, No. 454 Hospital of PLA, Nanjing, China. 3. Department of Vascular Surgery, Changhai Hospital, Second Military Medical University, Shanghai, China. Electronic address: zhoujian1-2@163.com. 4. Department of Vascular Surgery, Changhai Hospital, Second Military Medical University, Shanghai, China. Electronic address: xueguanky@163.com.
Abstract
OBJECTIVE: The aim of this study was to determine the role of smooth muscle 22 (SM22) in aortic dissection (AD) vascular remodeling and its regulatory mechanism on vascular smooth muscle cell function. METHODS: Seven patients who underwent surgery for AD with no genetic predisposition and seven organ donors who died from nonvascular diseases were selected. In each aorta sample, the levels of SM22 were detected using immunohistochemistry and Western blot analysis. We inhibited the expression of SM22 with the application of RNA interference in human aortic smooth muscle cells (HASMCs). Cell-counting Kit-8 (Dojindo, Kumamoto, Japan) analyses were used to detect HASMC proliferation. Furthermore, the intracellular calcium concentration was detected using Rhod-2/AM (Dojindo) staining. RESULTS: SM22 was significantly downregulated in the media of AD samples compared with controls (P < .05). In an in vitro study, downregulation of SM22 can significantly promote HASMC proliferation. Our research further revealed that cells treated with nifedipine can inhibit the promoter activity of SM22 downregulation on HASMC proliferation. Intracellular calcium concentration was a significantly varied during the process. CONCLUSIONS: SM22 regulates HASMC function activity through intracellular calcium. It presents a downregulation in AD, which might play a potential role in vascular remodeling of AD.
OBJECTIVE: The aim of this study was to determine the role of smooth muscle 22 (SM22) in aortic dissection (AD) vascular remodeling and its regulatory mechanism on vascular smooth muscle cell function. METHODS: Seven patients who underwent surgery for AD with no genetic predisposition and seven organ donors who died from nonvascular diseases were selected. In each aorta sample, the levels of SM22 were detected using immunohistochemistry and Western blot analysis. We inhibited the expression of SM22 with the application of RNA interference in human aortic smooth muscle cells (HASMCs). Cell-counting Kit-8 (Dojindo, Kumamoto, Japan) analyses were used to detect HASMC proliferation. Furthermore, the intracellular calcium concentration was detected using Rhod-2/AM (Dojindo) staining. RESULTS:SM22 was significantly downregulated in the media of AD samples compared with controls (P < .05). In an in vitro study, downregulation of SM22 can significantly promote HASMC proliferation. Our research further revealed that cells treated with nifedipine can inhibit the promoter activity of SM22 downregulation on HASMC proliferation. Intracellular calcium concentration was a significantly varied during the process. CONCLUSIONS:SM22 regulates HASMC function activity through intracellular calcium. It presents a downregulation in AD, which might play a potential role in vascular remodeling of AD.
Authors: Christian L Lino Cardenas; Chase W Kessinger; Carolyn MacDonald; Arminder S Jassar; Eric M Isselbacher; Farouc A Jaffer; Mark E Lindsay Journal: JCI Insight Date: 2018-03-08
Authors: Christian L Lino Cardenas; Chase W Kessinger; Yisha Cheng; Carolyn MacDonald; Thomas MacGillivray; Brian Ghoshhajra; Luai Huleihel; Saifar Nuri; Ashish S Yeri; Farouc A Jaffer; Naftali Kaminski; Patrick Ellinor; Neal L Weintraub; Rajeev Malhotra; Eric M Isselbacher; Mark E Lindsay Journal: Nat Commun Date: 2018-03-08 Impact factor: 14.919
Authors: Karlijn B Rombouts; Tara A R van Merrienboer; Johannes C F Ket; Natalija Bogunovic; Jolanda van der Velden; Kak Khee Yeung Journal: Eur J Clin Invest Date: 2021-11-21 Impact factor: 5.722